OSLO, Norway, March 3, 2026 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from China’s National Medical Products Administration (NMPA), enabling commercial launch in China.
Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure. With Cevira’s regulatory approval in China, Photocure is eligible for a milestone payment with further sales milestones based on future revenue.
The announcement from Asieris states: „As the world’s first non-surgical, non-invasive therapy for patients with cervical intraepithelial neoplasia grade 2 (CIN2), APL-1702 is expected to fill a critical clinical gap in this therapeutic area and redefine a massive, previously underserved market for non-invasive cervical disease treatment.
Den vollständigen Artikel hier lesen
6 Kommentare
Solid analysis. Will be watching this space.
This is very helpful information. Appreciate the detailed analysis.
I’ve been following this closely. Good to see the latest updates.
Good point. Watching closely.
Great insights on Fonds-News. Thanks for sharing!
Interesting update on Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions. Looking forward to seeing how this develops.